These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 33097350

  • 21. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
    Fu S, Wang T, Xu F.
    J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
    [Abstract] [Full Text] [Related]

  • 22. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
    Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K.
    Front Public Health; 2023 Sep; 11():1264056. PubMed ID: 38106883
    [Abstract] [Full Text] [Related]

  • 23. Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report.
    Hatakeyama Y, Ohnishi H, Suda K, Okamura K, Shimada T, Yoshimura S.
    J Oncol Pharm Pract; 2019 Dec; 25(8):2023-2026. PubMed ID: 30526346
    [Abstract] [Full Text] [Related]

  • 24. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.
    Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P.
    Curr Oncol; 2019 Feb; 26(1):e111-e114. PubMed ID: 30853817
    [Abstract] [Full Text] [Related]

  • 25. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

  • 26. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun 22; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 27. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
    Kedzior SK, Jacknin G, Hudler A, Mueller SW, Kiser TH.
    Am J Case Rep; 2021 Jun 29; 22():e931702. PubMed ID: 34185763
    [Abstract] [Full Text] [Related]

  • 28. A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab.
    Bazzi T, Gupta E, Mohamed A, Vashi M.
    Cureus; 2022 Sep 29; 14(9):e29537. PubMed ID: 36312693
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
    Wen L, Zou X, Chen Y, Bai X, Liang T.
    Front Immunol; 2020 Sep 29; 11():2076. PubMed ID: 32973816
    [Abstract] [Full Text] [Related]

  • 31. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 32. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
    Marsiglio J, McPherson JP, Kovacsovics-Bankowski M, Jeter J, Vaklavas C, Swami U, Grossmann D, Erickson-Wayman A, Soares HP, Kerrigan K, Gibson B, Doherty JA, Hyngstrom J, Hardikar S, Hu-Lieskovan S.
    Front Immunol; 2023 Sep 02; 14():1229823. PubMed ID: 37671166
    [Abstract] [Full Text] [Related]

  • 33. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
    Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebbé C, Gautier JF.
    Cancer Immunol Immunother; 2017 Nov 02; 66(11):1399-1410. PubMed ID: 28634815
    [Abstract] [Full Text] [Related]

  • 34. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
    Clotman K, Janssens K, Specenier P, Weets I, De Block CEM.
    J Clin Endocrinol Metab; 2018 Sep 01; 103(9):3144-3154. PubMed ID: 29955867
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Variability in clinical presentation of diabetes mellitus during anti-PD-1 immunotherapy.
    Bastin M, Mosbah H, Carlier A, Boudifa A, Villemain A, Hartemann A, Andreelli F.
    Diabetes Metab; 2020 Oct 01; 46(5):406-407. PubMed ID: 31034979
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab.
    Matsumura K, Nagasawa K, Oshima Y, Kikuno S, Hayashi K, Nishimura A, Okubo M, Uruga H, Kishi K, Kobayashi T, Mori Y.
    J Diabetes Investig; 2018 Mar 01; 9(2):438-441. PubMed ID: 28418115
    [Abstract] [Full Text] [Related]

  • 40. Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma.
    Munakata W, Ohashi K, Yamauchi N, Tobinai K.
    Int J Hematol; 2017 Mar 01; 105(3):383-386. PubMed ID: 27696192
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.